申请人:BANYU PHARMACEUTICAL CO., LTD.
公开号:EP1870401A1
公开(公告)日:2007-12-26
A compound represented by the formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 represents a branched lower alkyl group having from 3 to 9 carbon atoms or the like;
R2 represents a 6-membered heteroaryl group having 1 or 2 nitrogen atoms or the like;
R3 represents a hydrogen atom, an alkanoylamino group or the like;
R4 represents a hydrogen atom, a lower alkyl group or the like;
X1 represents an oxygen atom or a sulfur atom;
X2 represents an oxygen atom or a single bond; and
m indicates an integer of from 0 to 4.
This compound has a metabotropic glutamate receptor 1 inhibitory effect, and therefore is useful for the treatment of a brain disorder such as convulsion, acute pain, inflammatory pain, chronic pain, cerebral infraction or transient cerebral ischemic attack, a mental dysfunction such as schizophrenia, and a disease such as anxiety and drug addition.
式 (I) 所代表的化合物:
或其药学上可接受的盐,其中
R1 代表具有 3 至 9 个碳原子的支链低级烷基或类似基团;
R2 代表具有 1 或 2 个氮原子的 6 元杂芳基或类似基团
R3 代表氢原子、烷酰氨基或类似物;
R4 代表氢原子、低级烷基或类似物;
X1 代表氧原子或硫原子;
X2 代表氧原子或单键;以及
m 表示 0 至 4 的整数。
该化合物具有代谢型谷氨酸受体 1 抑制作用,因此可用于治疗抽搐、急性疼痛、炎症性疼痛、慢性疼痛、脑梗塞或短暂性脑缺血发作等脑部疾病,精神分裂症等精神功能障碍,以及焦虑和药物成瘾等疾病。